BioVinc is proud to announce that it has received a multi-million prestigious SBIR Phase II grant from the National Institutes of Health (NIH/NIAID). This grant will accelerate our efforts in the research and development of new treatments targeting the significant unmet medical need of prosthetic joint infections.
Deep bone infections, such as prosthetic joint infections, are notoriously difficult to treat and often pose life-threatening risks without drastic measures like amputation. These infections occur in 20-30% of open compound fractures, and while advancements in surgical techniques and infection prevention have lowered the incidence of orthopedic infections after hip or knee replacements, a small but persistent rate of infection—1-2%—remains in elective surgeries, according to the Surgical Care Improvement Project (SCIP). Furthermore, rates of recurrent or persistent infections following two-stage revision surgeries are alarmingly high, reaching up to 30-40%. Despite these challenges, effective therapies are still lacking.
BioVinc’s research team has developed an innovative bone-targeted therapy that has demonstrated the ability to eradicate deep bone infections, a major cause of infection recurrence. This NIH grant will support critical efficacy and preliminary safety evaluations, laying the foundation for future IND-enabling studies.
